Two studies into whether bisphosphonates are associated with oesophageal cancer have yielded contradictory conclusions. One published in the BMJ on 3 September.....

Intas Pharmaceuticals of India expects its oncology and oral solids businesses to drive growth as it hopes to scale the Rs20 billion ($429.8 million) turnover mark ahead of its proposed initial public offering (IPO) next year......

The World Health Organization is to publish two studies looking separately at the usage of monovalent pandemic H1N1 vaccine and the trivalent seasonal influenza jab to take stock of how these vaccines are used around the world. In the.....

Japan has publicly disclosed the first reported case of infection with a strain of bacteria carrying the NDM-1 "superbug" gene.

Dokkyo Medical University Hospital in Tochigi prefecture said that a male patient with an Escherichia coli.....

RaQualia Pharma, a Japanese venture spun out from Pfizer research, has reached a licensing deal for two of its pipeline projects with a leading South Korean pharma firm.

The agreement gives CJ CheilJedang exclusive rights in its home market and.....

Aurobindo Pharma of India has entered into a licensing deal with AstraZeneca for the supply of a range of solid dosage and sterile products for emerging markets. The agreement comes months after AstraZeneca struck a similar alliance with India's.....

India is setting up a task force to address various policy-related, inter-ministerial and other issues in the health sector, with the aim of creating a conducive environment for the growth of the domestic pharmaceutical industry.

With the US FDA issuing a rare refusal to file letter for Genentech's (Roche) trastuzumab-DM1 (T-DM1) to treat HER2-positive breast cancer on the basis of a single-arm Phase II trial that it submitted for accelerated approval, the company.....

Novartis and its collaborators have unveiled a new class of promising antimalarials – the spiroindolones. The lead candidate in the class, NITD609, yielded promising efficacy and safety data in in vitro and in vivo.....

Celldex Therapeutics suffered a sharp drop in its share price, wiping almost $40 million off its value to $113 million, following news that Pfizer is terminating their collaboration over rindopepimut, an investigational brain cancer vaccine.....

Glythera is to work with the US FDA's Center for Biologics Evaluation and Research to assess the feasibility of applying the UK-based biotech's PermaLink technology to the generation of synthetic carbohydrate-based conjugate vaccines......

MorphoSys has built further on its extensive history of partnering by gaining access to the Sheffield, UK-based biotech Absynth Biologics' novel target molecules associated with Staphylococcus aureus infections.

The German company's CEO.....

With the US FDA issuing a rare refusal to file letter for Genentech's (Roche) trastuzumab-DM1 (T-DM1) to treat HER2-positive breast cancer on the basis of a single-arm Phase II trial that it submitted for accelerated approval, the company is now.....

Tibotec Pharmaceuticals (J&J) has submitted a marketing authorisation application (MAA) to the EMA for TMC278 (rilpivirine), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV.

The.....

India has denied speculation of a "witch-hunt" targeting the local physicians who were involved in the controversial superbug study that was published in Lancet Infectious Diseases last month.

India's Drugs Controller General of India,.....

Astellas's US-based anticancer antibody subsidiary, Agensys, has begun clinical trials with an antibody-drug conjugate (ADC) for metastatic renal cancer, building on an alliance with Seattle Genetics which was expanded last year.

The ADC,.....

Taiwan's ScinoPharm is to make an investment in the US firm Tanvex Biologics, with the intention of building up joint capacity for the manufacture of biosimilars in the US market.

The investment will take the form of assets,.....

Forbion Capital Partners, the Netherlands-based life sciences-focused venture capitalist, has defied the moribund capital market by raising €190 million for two new funds, FCF I Co-Invest Fund and FCF II. As with Forbion's first fund, FCF I, the.....

We are delighted to announce the shortlist for the 6th Annual Scrip Awards. This year we were impressed with the calibre of the entries and we believe the shortlist, chosen by our judging panel of 19 industry experts, reflects the ground-breaking work.....

An editorial in New England Journal Medicine – penned to coincide with the